- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 3.1 EX-3.1
- 4.6 EX-4.6
- 4.7 EX-4.7
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 10.44 EX-10.44
- 10.52 EX-10.52
- 10.53 EX-10.53
- 21.1 EX-21.1
- 23.1 EX-23.1
- 31.1 EX-31.1
- 32.1 EX-32.1
- Download Excel data file
- View Excel data file
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Nos. 333-129884, 333-134280, 333-142701, 333-160496, 333-167925, 333-185433, 333-199304, 333-220804, 333-228291, 333-238090 and 333-241698) on Form S-8 and Registration Statements (Nos. 333-134279, 333-141014, 333-161453, 333-162160, 333-163517, 333-166444, 333-174292, 333-177793, 333-201826, 333-229555 and 333-232283) on Form S-3 of Alaunos Therapeutics, Inc. of our report dated March 30, 2022, relating to the financial statements of Alaunos Therapeutics, Inc. and subsidiaries, appearing in this Annual Report on Form 10-K of Alaunos Therapeutics, Inc. for the year ended December 31, 2021.
/s/ RSM US LLP
Boston, Massachusetts
March 30, 2022